Companies Alnylam Pharmaceuticals, Inc

Alnylam Pharmaceuticals (ALNY): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Alnylam Pharmaceuticals, Inc’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$14,867,600CEO Yvonne Greenstreet · source

Say-on-pay support92.89%Latest vote · source

CEO vs. named peers25th pct.Of 12 peer CEOs

CEO pay ratio48:1To the median employee · source

CEO pay, last three years

$8,895,670FY2023
$11,492,970FY2024
$14,867,600FY2025

CEO total pay was $14,867,600 in fiscal 2025, up from $11,492,970 in fiscal 2024.

FY2025: salary $1,404,200 · bonus $0 · stock awards $5,512,500 · option awards $4,363,380

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Alnylam Pharmaceuticals, Inc in fiscal 2025?

As disclosed, Yvonne Greenstreet (Chief Executive Officer) was the highest-paid executive at Alnylam Pharmaceuticals, Inc in fiscal 2025, with total compensation of $14,867,600.

How does Alnylam Pharmaceuticals, Inc's chief executive pay compare to its disclosed peer group?

As disclosed, Yvonne Greenstreet's total compensation ranked at the 25th percentile of Alnylam Pharmaceuticals, Inc's disclosed peer group.

What is Alnylam Pharmaceuticals, Inc's CEO-to-median employee pay ratio?

As disclosed, Alnylam Pharmaceuticals, Inc's CEO-to-median employee pay ratio was 48:1.

How did shareholders vote on Alnylam Pharmaceuticals, Inc's executive compensation?

As disclosed, 92.89% of shareholders supported Alnylam Pharmaceuticals, Inc's executive compensation in the latest say-on-pay vote.

How much does Alnylam Pharmaceuticals, Inc spend in total on board compensation for fiscal 2025?

As disclosed, Alnylam Pharmaceuticals, Inc reported total board compensation of $3,062,120 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Yvonne Greenstreet	$1,404,200	$0	$5,512,500	$4,363,380	$3,562,500	$0	$25,020	$14,867,600
Chief Executive Officer
Jeffrey Poulton	724,400	0	3,988,480	1,178,220	950,300	0	22,400	6,863,800
Executive Vice President, Chief Financial Officer
Bryan Supran	190,400	350,000	6,000,430	0	214,820	0	90,700	6,846,350
Executive Vice President, Chief Legal Officer and Secretary
Pushkal Garg	767,900	0	3,687,650	940,050	1,072,500	0	22,400	6,490,500
Executive Vice President, Chief Research and Development Officer
Tolga Tanguler	698,000	0	3,687,650	940,050	783,200	0	20,120	6,129,020
Executive Vice President, Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Yvonne Greenstreet	$14,867,600	$11,492,970	$8,895,670	↑ +3,374,630
Jeffrey Poulton	6,863,800	3,792,780	3,224,360	↑ +3,071,020
Bryan Supran	6,846,350	—	—	—
Pushkal Garg	6,490,500	2,919,190	3,231,090	↑ +3,571,310
Tolga Tanguler	6,129,020	2,754,570	2,869,710	↑ +3,374,450

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Alnylam's executive compensation philosophy is designed to align executive interests with the drivers of growth and stockholder returns, incentivize the execution of company strategy, and attract and retain talented executives with market-competitive pay. The program ensures that the substantial majority of NEO compensation is performance-based and at-risk, driving the growth of sustainable long-term stockholder value.

CEO STI target (% of salary)	125%
CEO LTI target (% of salary)	—
Independent consultant	Pay Governance
Clawback policy	true
Anti-hedging	true
Anti-pledging	true

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Pushkal Garg	PSU	2025-03-03	3,871	7,741	—	15,482	$245,070
Yvonne Greenstreet	RSU	2025-03-03	—	—	17,965	—	4,375,000
Jeffrey Poulton	PSU	2025-03-03	4,851	9,702	—	19,404	307,150
Pushkal Garg	RSU	2025-03-03	—	—	14,137	—	3,442,580
Tolga Tanguler	OPTION	2025-03-03	—	—	7,819	—	940,050
Jeffrey Poulton	OPTION	2025-03-03	—	—	9,800	—	1,178,220
Pushkal Garg	OPTION	2025-03-03	—	—	7,819	—	940,050
Tolga Tanguler	PSU	2025-03-03	3,871	7,741	—	15,482	245,070
Tolga Tanguler	RSU	2025-03-03	—	—	14,137	—	3,442,580
Jeffrey Poulton	RSU	2025-03-03	—	—	15,117	—	3,681,330
Yvonne Greenstreet	PSU	2025-03-03	17,965	35,930	—	71,860	1,137,500
Yvonne Greenstreet	OPTION	2025-03-03	—	—	36,293	—	4,363,380
Bryan Supran	RSU	2025-10-01	—	—	13,026	—	6,000,430

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Pushkal Garg	$3,442,580	$245,070	$940,050	5.3%
Yvonne Greenstreet	4,375,000	1,137,500	4,363,380	11.5%
Jeffrey Poulton	3,681,330	307,150	1,178,220	5.9%
Tolga Tanguler	3,442,580	245,070	940,050	5.3%
Bryan Supran	6,000,430	0	0	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Jeffrey Poulton	Option	1,151	147.47	—
Tolga Tanguler	Option	1,151	147.47	—
Pushkal Garg	Option	1,508	147.47	—
Tolga Tanguler	RSU	1,666	—	662,485
Jeffrey Poulton	RSU	1,908	—	758,716
Pushkal Garg	RSU	1,908	—	758,716
Yvonne Greenstreet	Option	1,985	147.47	—
Pushkal Garg	RSU	3,167	—	1,259,358
Tolga Tanguler	RSU	3,167	—	1,259,358
Tolga Tanguler	Option	3,235	190.01	—
Jeffrey Poulton	Option	3,703	190.01	—
Pushkal Garg	Option	3,703	190.01	—
Pushkal Garg	RSU	3,800	—	1,511,070
Tolga Tanguler	RSU	3,800	—	1,511,070
Jeffrey Poulton	RSU	5,160	—	2,051,874
Pushkal Garg	Option	5,220	152.61	—
Tolga Tanguler	Option	5,220	152.61	—
Yvonne Greenstreet	RSU	5,921	—	2,354,486
Jeffrey Poulton	RSU	6,193	—	2,462,646
Tolga Tanguler	RSU	7,000	—	2,783,550
Pushkal Garg	Option	7,819	243.53	—
Tolga Tanguler	Option	7,819	243.53	—
Jeffrey Poulton	RSU	8,013	—	3,186,369
Pushkal Garg	RSU	8,013	—	3,186,369
Jeffrey Poulton	Option	8,504	152.61	—
Jeffrey Poulton	Option	9,800	243.53	—
Yvonne Greenstreet	Option	11,493	190.01	—
Bryan Supran	RSU	13,026	—	5,179,789
Pushkal Garg	RSU	14,137	—	5,621,578
Tolga Tanguler	RSU	14,137	—	5,621,578
Jeffrey Poulton	RSU	15,117	—	6,011,275
Pushkal Garg	RSU	15,482	—	6,156,417
Tolga Tanguler	RSU	15,482	—	6,156,417
Yvonne Greenstreet	RSU	15,836	—	6,297,185
Yvonne Greenstreet	RSU	17,965	—	7,143,782
Yvonne Greenstreet	RSU	19,003	—	7,556,543
Jeffrey Poulton	RSU	19,404	—	7,716,001
Yvonne Greenstreet	RSU	24,867	—	9,888,363
Yvonne Greenstreet	Option	26,097	152.61	—
Yvonne Greenstreet	Option	36,293	243.53	—
Yvonne Greenstreet	RSU	71,860	—	28,575,129

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Michael W. BonneyNot independent · Departed during FY	$55,270	$360,320	$325,540	$0	$0	$741,130
Amy W. SchulmanIndependent · Board Chair · Nominating and Corporate Governance · People, Culture and Compensation	141,460	200,220	199,630	0	0	541,310
Colleen F. ReitanIndependent · Audit · People, Culture and Compensation (Chair)	92,500	200,220	199,630	0	0	492,350
Elliott Sigal, M.D., Ph.DIndependent · People, Culture and Compensation · Science and Technology	86,460	200,220	199,630	0	—	486,310
Peter N. KelloggIndependent · Audit (Chair)	85,000	200,220	199,630	0	0	484,850
Olivier Brandicourt, M.DIndependent · Audit · People, Culture and Compensation	82,500	200,220	199,630	0	0	482,350
David E.I. PyottIndependent · Nominating and Corporate Governance · Science and Technology	80,000	200,220	199,630	0	0	479,850
Dennis A. Ausiello, M.DIndependent · Science and Technology	80,000	200,220	199,630	0	0	479,850
Carolyn R. Bertozzi, Ph.DIndependent · Science and Technology · Departed during FY	73,700	200,220	199,630	0	—	473,550
Margaret A. Hamburg, M.DIndependent · Nominating and Corporate Governance · Science and Technology	70,000	200,220	199,630	0	0	469,850
Phillip A. Sharp, Ph.DIndependent · Science and Technology · Departed during FY	45,920	0	0	0	7,010	52,930
Yvonne L. Greenstreet, M.DEmployee director	0	0	0	—	0	0
Stuart A. ArbuckleIndependent · Science and Technology · Newly elected	0	0	0	0	0	0

Board fee structure and ownership guideline

Annual cash retainer	$60,000
Annual equity retainer	$400,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	25,000 / 20,000 / 20,000
Stock ownership guideline	$5

Total cost of the board

Component	FY2025
Cash retainers and fees	$892,810
Equity awards (grant-date value)	$2,162,300
All other compensation	$7,010
Total cost of the board	$3,062,120

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Alnylam Pharmaceuticals as a peer

Companies that benchmark against ALNY

20 companies name ALNY as a compensation peer

Amphastar Pharmaceuticals, Inc.AMPHFY2025
BeOne Medicines Ltd.ONCFY2025
BIOGEN INC.BIIBFY2025
BIOMARIN PHARMACEUTICAL INCBMRNFY2025
EXACT SCIENCES CORPEXASFY2024
EXELIXIS, INC.EXELFY2025
Guardant Health, Inc.GHFY2025
INCYTE CORPIFY2025
INCYTE CORPINCYFY2025
INSMED IncINSMFY2025
Jazz Pharmaceuticals plcJAZZFY2025
MADRIGAL PHARMACEUTICALS, INC.MDGLFY2025
Moderna, Inc.MRNAFY2025
Natera, Inc.NTRAFY2025
NEUROCRINE BIOSCIENCES INCNBIXFY2025
NovoCure LtdNVCRFY2025
REGENERON PHARMACEUTICALS, INC.REGNFY2025
Sarepta Therapeutics, Inc.SRPTFY2025
Supernus, Inc.INDVFY2025
Supernus, Inc.SUPNFY2025
UNITED THERAPEUTICS CorpUTHRFY2025
Vaxcyte, Inc.PCVXFY2025

Each company listed discloses ALNY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALNY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

GILD Gilead Sciences, Inc.INCY Incyte CorporationBMRN BioMarin Pharmaceutical Inc.EXAS Exact Sciences CorporationNBIX Neurocrine Biosciences, Inc.VRTX Vertex Pharmaceuticals IncorporatedSRPT Sarepta Therapeutics, Inc.ONC BeOne Medicines, Ltd.BIIB Biogen Inc.UTHR United Therapeutics CorporationMRNA Moderna, Inc.REGN Regeneron Pharmaceuticals, Inc.

Peer reciprocity

The companies Alnylam Pharmaceuticals, Inc names as compensation peers that name it back in their own disclosed peer groups.

Incyte Corporation (INCY)⁹¹BioMarin Pharmaceutical Inc. (BMRN)⁹²Exact Sciences Corporation (EXAS)⁹³Neurocrine Biosciences, Inc. (NBIX)⁹⁴Sarepta Therapeutics, Inc. (SRPT)⁹⁵BeOne Medicines, Ltd. (ONC)⁹⁶United Therapeutics Corporation (UTHR)⁹⁷Moderna, Inc. (MRNA)⁹⁸Regeneron Pharmaceuticals, Inc. (REGN)⁹⁹

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Incyte Corporation	2025	William Meury	$647,260	$27,509,657	$2,573,998	$1,300,000	$32,085,952
2	Gilead Sciences, Inc.	2025	Daniel O'Day	1,795,192	15,238,402	4,500,060	4,848,120	28,437,198
3	Biogen Inc.	2025	Christopher Viehbacher	1,727,885	18,368,875	0	3,190,875	23,646,004
4	BioMarin Pharmaceutical Inc.	2025	Alexander Hardy	1,130,769	16,833,629	1,909,310	1,644,500	21,927,563
5	Vertex Pharmaceuticals Incorporated	2025	Reshma Kewalramani	1,600,000	15,002,270	0	4,118,640	21,144,261
6	Moderna, Inc.	2025	Stéphane Bancel	1,677,739	6,897,455	6,897,425	4,302,360	19,932,217
7	United Therapeutics Corporation	2025	Martine Rothblatt	1,545,005	6,067,990	6,075,804	4,281,875	18,038,972
8	BeOne Medicines, Ltd.	2025	John Oyler	1,133,000	11,249,615	3,749,967	1,676,840	17,943,521
9	Exact Sciences Corporation	2024	Kevin Conroy	1,083,368	13,496,138	0	712,329	15,539,378
10	Alnylam Pharmaceuticals, Inc	2025	Yvonne Greenstreet	1,404,200	5,512,500	4,363,380	3,562,500	14,867,600
11	Neurocrine Biosciences, Inc.	2025	Kyle Gano	920,000	5,750,023	5,750,006	0	13,448,935
12	Sarepta Therapeutics, Inc.	2025	Douglas Ingram	1,171,425	6,000,005	0	649,000	7,840,666
13	Regeneron Pharmaceuticals, Inc.	2025	Leonard Schleifer	1,979,922	—	—	3,682,655	7,280,549

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Alnylam Pharmaceuticals, Inc	200%	PSU 50 · RSU 25 · Option 25	No	Pay Governance
BeOne Medicines, Ltd.	148%	PSU 50 · Options 25 · RSU 25	No	Pay Governance
Biogen Inc.	127%	PSU 60 · RSU 40	Yes	Pay Governance
BioMarin Pharmaceutical Inc.	130%	PSU 66 · RSU 21 · Options 13	Yes — Relative TSR	Aon Human Capital Solutions
Exact Sciences Corporation	47%	PSU 60 · RSU 40	No	Aon
Gilead Sciences, Inc.	180%	PSU 50 · Option 25 · RSU 25	Yes — Relative TSR	FW Cook
Incyte Corporation	138.6%	PSU 60 · RSU 20 · Option 20	Yes — relative total shareholder return (TSR)	Aon
Moderna, Inc.	170%	PSU 50 · Options 50	No	Pay Governance LLC
Neurocrine Biosciences, Inc.	105%	Option 50 · PRSU 30 · RSU 20	No	Frederic W. Cook & Co., Inc.
Regeneron Pharmaceuticals, Inc.	155%	Options 60 · RSU 40	not disclosed	Pay Governance LLC
Sarepta Therapeutics, Inc.	100%	PSU 50 · Option 25 · RSU 25	No	FW Cook
United Therapeutics Corporation	221%	PSO 50 · PSU 50	No	Aon
Vertex Pharmaceuticals Incorporated	not disclosed	PSU 55 · RSU 45	No	Pearl Meyer

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-03-25	111,772,389	8,552,534	41,495	92.89%	Passed
2025	2025-05-08	111,725,907	6,909,706	29,274	94.18%	Passed
2024	2024-05-16	106,783,262	6,133,628	29,162	94.57%	Passed
2023	2023-05-18	109,696,830	4,017,474	18,098	96.47%	Passed
2022	2022-05-18	95,318,086	10,517,203	24,526	90.06%	Passed
2021	2021-05-18	81,382,437	20,146,079	186,307	80.16%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-03-25	92.89%^a
2025	2025-05-08	94.18%^b
2024	2024-05-16	94.57%^c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of Proposal 2.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as shares voting on this matter and accordingly will have no effect on the approval of this Proposal 3.”.

c. Approved under the standard stated in the filing — “Accordingly, abstentions and broker non-votes, if any, would have no effect on the vote for any of the Proposals to be considered at the annual meeting, because these Proposals are based on a percentage of the votes that are actually cast at the annual meeting.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	48 : 1
CEO total compensation	$14,867,600
Median employee compensation	$312,180

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	199	$334	$66,454	Common	Form 4 ↗
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	293	332	97,244	Common	Form 4 ↗
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	829	330	273,951	Common	Form 4 ↗
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	909	330	299,752	Common	Form 4 ↗
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	56	320	17,928	Common	Form 4 ↗
Amy W. Schulman	Director	2026-05-13	D	11,250	0	0	Derivative, Class A Common	Form 4 ↗
Amy W. Schulman	Director	2026-05-13	A	11,250	70	789,750	Common	Form 4 ↗
Dividend-equivalent accruals		2026-05-20	—	13,330	—	—	9 insiders, 9 accrual rows
Dennis A. Ausiello	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Amy W. Schulman	Director	2026-05-20	A	838	0	0	RSU	Form 4 ↗
David E.I. Pyott	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Stuart A. Arbuckle	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Olivier Brandicourt	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Margaret A. Hamburg	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Charles Elliott Sigal	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Peter N. Kellogg	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Colleen F. Reitan	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	1,175	299	351,219	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	A	3,830	0	0	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	3,830	0	0	Derivative, Class A Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	17	303	5,145	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	495	301	148,856	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	1,222	300	366,441	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	921	298	274,191	Common	Form 4 ↗
Benjamin Cravatt	Director	2026-06-01	A	4,393	0	0	Derivative, Class A Common	Form 4 ↗
Yvonne Greenstreet	Director	2026-09-19	A	107	0	0	Common	Form 4 ↗
Bryan Supran	EVP, CLO and Secretary	2026-10-02	D	1,758	227	398,855	Common	Form 4 ↗
Amy W. Schulman	Director	2026-11-09	A	1,910	157	299,526	Common	Form 4 ↗
David E.I. Pyott	Director	2026-11-10	D	3,780	0	0	Derivative, Class A Common	Form 4 ↗
David E.I. Pyott	Director	2026-11-10	A	3,780	72	272,122	Common	Form 4 ↗
Charles Elliott Sigal	Director	2026-11-10	A	1,600	152	243,600	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 39 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	199	$334	$66,454	Common	Form 4 ↗
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	293	332	97,244	Common	Form 4 ↗
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	829	330	273,951	Common	Form 4 ↗
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	909	330	299,752	Common	Form 4 ↗
Melissa McLaughlin	Chief Human Resources Officer	2026-04-06	D	56	320	17,928	Common	Form 4 ↗
Amy W. Schulman	Director	2026-05-13	D	11,250	0	0	Derivative, Class A Common	Form 4 ↗
Amy W. Schulman	Director	2026-05-13	A	11,250	70	789,750	Common	Form 4 ↗
Dennis A. Ausiello	Director	2026-05-20	A	1,441	0	0	Derivative, Class A Common	Form 4 ↗
Dennis A. Ausiello	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Amy W. Schulman	Director	2026-05-20	A	838	0	0	RSU	Form 4 ↗
Charles Elliott Sigal	Director	2026-05-20	A	1,441	0	0	Derivative, Class A Common	Form 4 ↗
Stuart A. Arbuckle	Director	2026-05-20	A	1,441	0	0	Derivative, Class A Common	Form 4 ↗
David E.I. Pyott	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
David E.I. Pyott	Director	2026-05-20	A	1,441	0	0	Derivative, Class A Common	Form 4 ↗
Stuart A. Arbuckle	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Olivier Brandicourt	Director	2026-05-20	A	1,441	0	0	Derivative, Class A Common	Form 4 ↗
Amy W. Schulman	Director	2026-05-20	A	1,802	0	0	Derivative, Class A Common	Form 4 ↗
Olivier Brandicourt	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Colleen F. Reitan	Director	2026-05-20	A	1,441	0	0	Derivative, Class A Common	Form 4 ↗
Margaret A. Hamburg	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Charles Elliott Sigal	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Peter N. Kellogg	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Colleen F. Reitan	Director	2026-05-20	A	671	0	0	RSU	Form 4 ↗
Margaret A. Hamburg	Director	2026-05-20	A	1,441	0	0	Derivative, Class A Common	Form 4 ↗
Peter N. Kellogg	Director	2026-05-20	A	1,441	0	0	Derivative, Class A Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	1,175	299	351,219	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	A	3,830	0	0	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	3,830	0	0	Derivative, Class A Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	17	303	5,145	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	495	301	148,856	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	1,222	300	366,441	Common	Form 4 ↗
David E.I. Pyott	Director	2026-06-01	D	921	298	274,191	Common	Form 4 ↗
Benjamin Cravatt	Director	2026-06-01	A	4,393	0	0	Derivative, Class A Common	Form 4 ↗
Yvonne Greenstreet	Director	2026-09-19	A	107	0	0	Common	Form 4 ↗
Bryan Supran	EVP, CLO and Secretary	2026-10-02	D	1,758	227	398,855	Common	Form 4 ↗
Amy W. Schulman	Director	2026-11-09	A	1,910	157	299,526	Common	Form 4 ↗
David E.I. Pyott	Director	2026-11-10	D	3,780	0	0	Derivative, Class A Common	Form 4 ↗
David E.I. Pyott	Director	2026-11-10	A	3,780	72	272,122	Common	Form 4 ↗
Charles Elliott Sigal	Director	2026-11-10	A	1,600	152	243,600	Common	Form 4 ↗

Sources (99 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Yvonne Greenstreet. DEF 14A, filed 2026-04-06. Section “Executive Compensation”. As printed: 14,867,600. View filing ↗
Section 01, Jeffrey Poulton. DEF 14A, filed 2026-04-06. Section “Executive Compensation”. As printed: 6,863,800. View filing ↗
Section 01, Bryan Supran. DEF 14A, filed 2026-04-06. Section “Executive Compensation”. As printed: 6,846,350. View filing ↗
Section 01, Pushkal Garg. DEF 14A, filed 2026-04-06. Section “Executive Compensation”. As printed: 6,490,500. View filing ↗
Section 01, Tolga Tanguler. DEF 14A, filed 2026-04-06. Section “Executive Compensation”. As printed: 6,129,020. View filing ↗
Section 03, Pushkal Garg PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Yvonne Greenstreet RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Jeffrey Poulton PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Pushkal Garg RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Tolga Tanguler OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Jeffrey Poulton OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Pushkal Garg OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Tolga Tanguler PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Tolga Tanguler RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Jeffrey Poulton RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Yvonne Greenstreet PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Yvonne Greenstreet OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Bryan Supran RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-06. Section “CEO Pay Ratio”. As printed: 48 : 1. View filing ↗
Section 08, Michael W. Bonney. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 741,130. View filing ↗
Section 08, Amy W. Schulman. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 541,310. View filing ↗
Section 08, Colleen F. Reitan. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 492,350. View filing ↗
Section 08, Elliott Sigal, M.D., Ph.D. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 486,310. View filing ↗
Section 08, Peter N. Kellogg. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 484,850. View filing ↗
Section 08, Olivier Brandicourt, M.D. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 482,350. View filing ↗
Section 08, David E.I. Pyott. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 479,850. View filing ↗
Section 08, Dennis A. Ausiello, M.D. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 479,850. View filing ↗
Section 08, Carolyn R. Bertozzi, Ph.D. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 473,550. View filing ↗
Section 08, Margaret A. Hamburg, M.D. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 469,850. View filing ↗
Section 08, Phillip A. Sharp, Ph.D. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 52,930. View filing ↗
Section 08, Yvonne L. Greenstreet, M.D. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, Stuart A. Arbuckle. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Melissa McLaughlin 2026-04-06. Form 4, filed 2026-04-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Melissa McLaughlin 2026-04-06. Form 4, filed 2026-04-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Melissa McLaughlin 2026-04-06. Form 4, filed 2026-04-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Melissa McLaughlin 2026-04-06. Form 4, filed 2026-04-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Melissa McLaughlin 2026-04-06. Form 4, filed 2026-04-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Amy W. Schulman 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Amy W. Schulman 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dennis A. Ausiello 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dennis A. Ausiello 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Amy W. Schulman 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Elliott Sigal 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stuart A. Arbuckle 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stuart A. Arbuckle 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Olivier Brandicourt 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Amy W. Schulman 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Olivier Brandicourt 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Colleen F. Reitan 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Margaret A. Hamburg 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Elliott Sigal 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Peter N. Kellogg 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Colleen F. Reitan 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Margaret A. Hamburg 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Peter N. Kellogg 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Benjamin Cravatt 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Yvonne Greenstreet 2026-09-19. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Bryan Supran 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Amy W. Schulman 2026-11-09. Form 4, filed 2026-11-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-11-10. Form 4, filed 2026-11-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David E.I. Pyott 2026-11-10. Form 4, filed 2026-11-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Elliott Sigal 2026-11-10. Form 4, filed 2026-11-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-05-27. Item 5.07 · say-on-pay result. As reported: 92.89% (votes for as printed: 111,772,389). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-05-13. Item 5.07 · say-on-pay result. As reported: 94.18% (votes for as printed: 111,725,907). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-05-20. Item 5.07 · say-on-pay result. As reported: 94.57% (votes for as printed: 106,783,262). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 892,810 + equity 2,162,300 + all other 7,010 = 3,062,120, summed across the director compensation table rows.
Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
Gilead Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. View filing ↗
Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
Vertex Pharmaceuticals Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. View filing ↗
Moderna, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. View filing ↗
United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
BeOne Medicines, Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in BeOne Medicines, Ltd.'s own proxy. As printed: 17,943,521. View filing ↗
Exact Sciences Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. View filing ↗
Alnylam Pharmaceuticals, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc's own proxy. As printed: 14,867,600. View filing ↗
Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
Sarepta Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. View filing ↗
Regeneron Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. View filing ↗
Section 10a, Incyte Corporation reciprocity. DEF 14A. Incyte Corporation names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, BioMarin Pharmaceutical Inc. reciprocity. DEF 14A. BioMarin Pharmaceutical Inc. names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Exact Sciences Corporation reciprocity. DEF 14A. Exact Sciences Corporation names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Neurocrine Biosciences, Inc. reciprocity. DEF 14A. Neurocrine Biosciences, Inc. names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Sarepta Therapeutics, Inc. reciprocity. DEF 14A. Sarepta Therapeutics, Inc. names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, BeOne Medicines, Ltd. reciprocity. DEF 14A. BeOne Medicines, Ltd. names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, United Therapeutics Corporation reciprocity. DEF 14A. United Therapeutics Corporation names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Moderna, Inc. reciprocity. DEF 14A. Moderna, Inc. names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Regeneron Pharmaceuticals, Inc. reciprocity. DEF 14A. Regeneron Pharmaceuticals, Inc. names Alnylam Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗